Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Off topic but amazing

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Jan 30, 2024 2:36pm

70 Views

Post# 35853211

RE:RE:RE:RE:RE:RE:Off topic but amazing

Unless Th1902 works how do you plan to attract such a captain.... Nash is dead... Egrifta unpatented... Trogarzo a 300 patients drug instead of 3000 like forecasted.... 60M dept @ 15%+, 40M in cash or what's left of it, EDITDA positive for a quarter maybe more who knows.... a BOD of deception and bad decisions since the departure of Paul Pommier.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario